Glucagon-like peptide-1 (GLP-1) agonists are a class of drugs that mimic the action of GLP-1, which is a naturally occurring peptide hormone in the human body that is mainly responsible for regulating insulin, blood sugar levels, and appetite
On one hand, the lack of approval means no established treatment protocols exist, insurance will not cover costs, and medical supervision may be limited
Their focus on growth-hormone peptide stacks (CJC-1295, Ipamorelin, Sermorelin) and longevity peptides like Epitalon and MOTS-C aligns well with the most in-demand peptide categories in 2026
The oral GLP-1 medications has also matured as a viable alternative to injectables
Smaller, more frequent meals of four to five modest portions per day are generally better tolerated than conventional three-meal patterns when gastric emptying is delayed
It's designed with a novel basket trial approach simultaneously evaluating retatrutide across multiple adiposity-related disease states